Trial Profile

The Safety and Feasibility of UMC119-06 Cell Therapy in Subjects With Chronic Obstructive Pulmonary Disease

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UMC119 06 (Primary)
Indications Chronic obstructive pulmonary disease
Focus Adverse reactions
Sponsors Meridigen Biotech

Most Recent Events

04 Dec 2022 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.
04 Dec 2022 Planned primary completion date changed from 31 Mar 2022 to 31 Dec 2023.
04 Dec 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com